Eiger announces PRIME designation granted by EMA for lonafarnib for treatment of HDV
Eiger BioPharmaceuticals announced the EMA has granted PRIME (PRIority MEdicines) designation for lonafarnib for treatment of hepatitis delta virus infection. Eiger's application was supported by data from Phase 2 clinical studies of lonafarnib treatment in HDV-infected patients. December 18, 2018